



(51) International Patent Classification:

C07D 471/04 (2006.01) *A61P 25/28* (2006.01)
A61K 31/4985 (2006.01)

(21) International Application Number:

PCT/IB2013/058347

(22) International Filing Date:

6 September 2013 (06.09.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/703,969 21 September 2012 (21.09.2012) US

(71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **AM ENDE, Christopher William**; 32 Hunting Ridge Drive, Mystic, Connecticut 06355 (US). **GREEN, Michael Eric**; 22 Ward Street, Apt #2, Boston, Massachusetts 02127 (US). **JOHNSON, Douglas Scott**; 85 Adin Drive, Concord, Massachusetts 01742 (US). **KAUFFMAN, Gregory Wayne**; 30 Boulder Way, East Greenwich, Rhode Island 02818 (US). **O'DONNELL, Christopher John**; 71 Oxford Court, Mystic, Connecticut 06355 (US). **PATEL, Nandini Chaturbhai**; 70 Hope Avenue, Apt. 205, Waltham, Massachusetts 02453 (US). **PETERSSON, Martin Youngjin**; 3 Gilson Road, Littleton, Massachusetts 01460 (US). **STEPAN, Antonia Friederike**; 50 Park Row West, Apt. 420, Providence, Rhode Island 02903 (US). **STIFF, Cory Michael**; 883

Montauk Avenue, Apt. 4, New London, Connecticut 06320 (US). **SUBRAMANYAM, Chakrapani**; 314 Great Pond Road, South Glastonbury, Connecticut 06733 (US). **TRAN, Tuan Phong**; 106 Church Hill Road, Ledyard, Connecticut 06339 (US). **VERHOEST, Patrick Robert**; 23 Calvin Road, Newton, Massachusetts 02460 (US).


(74) Agent: **KLEIMAN, Gabriel L.**; Pfizer Inc., 235 East 42nd Street, New York, New York 10017 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NOVEL BICYCLIC PYRIDINONES



I

(57) Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

**Declarations under Rule 4.17:**

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*